Bishii Febraayo 2023, Maamulka Cuntada iyo Dawooyinka (FDA) ayaa dardar galiyay oggolaanshaha tucatinib (Tukisa, Seagen Inc.) iyo trastuzumab ee daawaynta RAS-nooca duurjoogta ah ee HER2-positive kansarka mindhicirka oo faafay ama aan noqon karin rem.